Table 3.
Survival outcomes of patients with IPMN and MCN in different stages.
| Outcomes | Localized | Regional | Distant | ||||
|---|---|---|---|---|---|---|---|
| IPMN (n = 339) | MCN(n = 98) | IPMN (n = 827) | MCN(n = 71) | IPMN (n = 1,134) | MCN(n = 36) | ||
| Overall survival | 1 year | 82.4% | 90.7% | 62.6% | 63.4% | 23.8% | 26.0% |
| 3 year | 65.0% | 79.7% | 29.0% | 30.7% | 4.2% | 5.8% | |
| 5 year | 56.2% | 74.6% | 19.4% | 26.3% | 2.5% | 2.9% | |
| Median | NA | NA | 18 months | 20 months | 6 months | 6 months | |
| Cancer-specific survival | 1 year | 83.5% | 95.6% | 64.8% | 67.0% | 25.5% | 26.7% |
| 3 year | 68.9% | 88.2% | 31.3% | 34.5% | 4.6% | 6.0% | |
| 5 year | 63.0% | 85.8% | 22.2% | 31.7% | 2.9% | 3.0% | |
| Median | NA | NA | 20 months | 23 months | 6 months | 7 months | |
IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm.